Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin

Clinical Pharmacokinetics

Volumn 46, Issue 3, 2007, Pages 247-259

  Chandra, Richa ^a   Liu, Ping ^a   Breen, Jeanne D ^a   Fisher, Jeannine ^a   Xie, Charles ^a   LaBadie, Robert ^a   Benner, Rebecca J ^a   Benincosa, Lisa J ^a   Sharma, Amarnath ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AZITHROMYCIN; MICROSPHERE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULARY; DRUG RELEASE; DRUG TOLERABILITY; ELECTROCHEMISTRY; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL TRACT; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID DIET; MAJOR CLINICAL STUDY; MALE; NAUSEA; NAUSEA AND VOMITING; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; ANTACIDS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIETARY FATS; DRUG INTERACTIONS; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; SAMPLE SIZE;

EID: 33947269104     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746030-00005     Document Type: Article

References (30)

1. Pfizer, Inc. Zithromax® (azithromycin tablets) and (azithromycin for oral suspension) [online]. New York (NY): Pfizer, Inc., 2004. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zithromax.pdf [Accessed 2007 Jan 30]
2. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9 (3 Suppl.): 38-44
3. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993; 31 (E Suppl.): 39-50
4. Girard D, Bergeron JM, Milisen WB, et al. Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. J Antimicrob Chemother 1993; 31 (E Suppl.): 17-28
5. Girard D, Finegan SM, Dunne MW, et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 2005; 56: 365-71
6. Craig WA. The hidden impact of antibacterial resistance in respiratory tract infection: re-evaluating current antibiotic therapy. Respir Med 2001; 95 (A Suppl.): S12-9
7. Pfizer, Inc. Zithromax® (azithromycin for injection): for IV infusion only [online]. New York (NY): Pfizer, Inc., 2003. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zithromaxIV.pdf [Accessed 2007 Jan 30]
8. Periti P, Mazzei T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346-64
9. Weber Jr FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 485-90
10. Data on file, Pfizer Inc., 2002
11. US FDA. Draft guidance for industry: bioavailability and bioequivalence studies for orally administered drug products - general considerations [online]. Rockville (MD): US FDA, 2002. Available from URL: http://www.fda.gov/cder/ guidance/4964dft.htm [Accessed 2007 Jan 30]
12. Taninaka C, Ohtani H, Hanada E, et al. Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr B Biomed Sci Appl 2000; 738: 405-11
13. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001; 29 (2 Suppl.): 11-5
14. Noreddin AM, Roberts D, Nichol K, et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCRpositive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46: 4029-34
15. Zhanel GG, Johanson C, Hisanaga T, et al. Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations. J Antimicrob Chemother 2004; 54: 1072-7
16. Darkes MJ, Perry CM. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2003; 2: 175-201
17. Perez-Gorricho B, Ripoll M. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents 2003; 21: 222-8
18. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005; 118 (7A Suppl.): 21S-8S
19. Azithromycin extended-release (Zmax) for sinusitis and pneumonia. Med Lett Drugs Ther 2005; 47: 78-80
20. Drehobl MA, De Salvo MC, Lewis DE, et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128: 2230-7
21. Pfizer, Inc. Zmax™ (azithromycin extended release) for oral suspension [online]. New York (NY): Pfizer, Inc., 2005. Available from URL: http://www.pfizer.com/pfizer/download/uspi_zmax.pdf [Accessed 2007 Jan 30]
22. Feighner SD, Tan CP, McKee KK, et al. Receptor for motilin identified in the human gastrointestinal system. Science 1999; 284: 2184-8
23. Takeshita E, Matsuura B, Dong M, et al. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol 2006; 41: 223-30
24. Peeters TL, Bormans V, Vantrappen G. Comparison of motilin binding to crude homogenates of human and canine gastrointestinal smooth muscle tissue. Regul Pept 1988; 23: 171-82
25. Data on file, Pfizer Inc., 1994
26. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990; 25 (A Suppl.): 39-47
27. Hurlimann S, Michel K, Inauen W, et al. Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers. Am J Gastroenterol 1996; 91: 1173-80
28. Data on file, Pfizer Inc., 2004
29. Amsden GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1500 milligrams, given over a 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999; 43: 163-5
30. Liu P, Allaudeen H, Chandra R, et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother 2007 Jan; 51 (1): 103-9